We are live on ! Find out more
OMC

OUP Management Company Portfolio holdings

AUM $44.5M
1-Year Est. Return 55.11%
This Fund
S&P 500
This Quarter Est. Return
-1.12%
1 Year Est. Return
+55.11%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$64.2M
AUM Growth
-$8.44M
Cap. Flow
-$3.87M
Cap. Flow %
-6.03%
Top 10 Hldgs %
94.89%
Holding
15
New
–
Increased
–
Reduced
4
Closed
–
Avg Time Held
3 quarters
Top 10 Avg Time Held
2.5 quarters
Top 20 Avg Time Held
3 quarters

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
EVLV icon
Evolv Technologies
EVLV
+$2.43M
2
IONQ icon
IonQ
IONQ
+$1.11M
3
LABP icon
Landos Biopharma, Inc. Common Stock
LABP
+$325K
4
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$13K

Sector Composition

Rank Sector Weight
1 Healthcare 88.55%
2 Technology 9.3%
3 Industrials 2.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$11.8M 18.39%
2,937,615
– –
2021 Q4
3 quarters
PMVP icon
2
PMV Pharmaceuticals
PMVP
$79.7M
$11.8M 18.33%
989,232
– –
2021 Q4
3 quarters
DICE icon
3
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$10.9M 16.95%
536,693
– –
2021 Q4
3 quarters
JBIO icon
4
Jade Biosciences
JBIO
$894M
$10M 15.59%
17,250
– –
2021 Q4
3 quarters
IONQ icon
5
IonQ
IONQ
$14.7B
$5.97M 9.3%
1,177,597
-200,000
-15% -$1.11M
2021 Q4
3 quarters
CYT
6
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$4.74M 7.38%
2,469,572
-5,000
-0.2% -$13K
2021 Q4
3 quarters
VOR icon
7
Vor Biopharma
VOR
$1.2B
$1.49M 2.32%
18,736
– –
2021 Q4
3 quarters
DTIL icon
8
Precision BioSciences
DTIL
$179M
$1.46M 2.28%
37,464
– –
2021 Q4
3 quarters
RNAC icon
9
Cartesian Therapeutics
RNAC
$213M
$1.42M 2.2%
28,751
– –
2021 Q4
3 quarters
EVLV icon
10
Evolv Technologies
EVLV
$792M
$1.38M 2.15%
652,475
-930,246
-59% -$2.43M
2021 Q4
3 quarters
LENZ icon
11
LENZ Therapeutics
LENZ
$116M
$1.29M 2.01%
58,044
– –
2021 Q4
3 quarters
LABP icon
12
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$804K 1.25%
123,767
-37,509
-23% -$325K
2021 Q4
3 quarters
EFTR icon
13
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$587K 0.91%
41,028
– –
2021 Q4
3 quarters
SPRO icon
14
Spero Therapeutics
SPRO
$70.5M
$498K 0.78%
249,070
– –
2021 Q4
3 quarters
QTTB icon
15
Q32 Bio
QTTB
$264M
$103K 0.16%
3,556
– –
2021 Q4
3 quarters

Similar funds

JMF
Johnson Midwest Financial Glidden, Iowa $44.7M AUM 21.66% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
MCAV
Meritech Capital Associates VI Palo Alto, California $45.3M AUM 4.6% 1-Year Est. Return
SIP
Scott Investment Partners Henley-On-Thames, United Kingdom $43.5M AUM 17.97% 1-Year Est. Return
KXA
KPCB XIV Associates Menlo Park, California $42.8M AUM 16.52% 1-Year Est. Return
WRCAI
West Rim Capital Associates II Lehi, Utah $46.8M AUM 11.72% 1-Year Est. Return
MAM
Must Asset Management Seoul, South Korea $40.9M AUM 22.53% 1-Year Est. Return
GIA
G2VP I Associates Portola Valley, California $48.2M AUM 37.59% 1-Year Est. Return

OUP Management Company's Q3 2022 Portfolio in Review

As of Q3 2022, OUP Management Company held 15 positions worth $64.2M, down 12% from $72.7M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

OUP Management Company withdrew a net $3.87M in Q3 2022, reducing 4 holdings. Its largest reduction was Evolv Technologies, cutting an estimated $2.43M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 86% a quarter earlier, followed by Technology and Industrials.

  • OUP Management Company's biggest Q3 2022 reduction was Evolv Technologies, cutting an estimated $2.43M.
  • OUP Management Company's ten largest holdings make up 95% of its $64.2M portfolio in Q3 2022.
  • OUP Management Company opened 0 new positions and closed 0 in Q3 2022.
  • OUP Management Company's portfolio value fell 12% quarter-over-quarter to $64.2M.

Based on OUP Management Company's 13F filing for Q3 2022, filed 1 Nov 2022.